Global Lennox Gastaut Syndrome Market – Industry Trends and Forecast to 2030

Lennox Gastaut Syndrome Market Analysis and Size

The ongoing pandemic is considerably changing the pharma and healthcare sector dynamics. Several hospitals, ambulatory surgical care centers and clinics globally are adopting advanced devices and equipment. Revenue growth of the Lennox Gastaut Syndrome market is considerably driven by factors such as increasing prevalence of chronic diseases, rapid advancements in healthcare and medical sector.

Data Bridge Market Research analyses a growth rate in the Lennox Gastaut syndrome market in the forecast period 2023-2030. The expected CAGR Lennox Gastaut syndrome market is tend to be around 4.60% in the mentioned forecast period. The market was valued at USD 700 million in 2022, and it would grow upto USD 1003.12 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Lennox Gastaut Syndrome Market Scope and Segmentation

Market Definition

Lennox-Gastaut syndrome (LGS) also known as pediatric epilepsy syndrome or childhood epileptic encephalopathy. It is usually characterized by mental retardation, reduced intellectual powder, multiple tonic-clonic seizures and strange findings on electroencephalography. It is most frequently observed between second and sixth year of the life.

Lennox Gastaut Syndrome Market Dynamics

Drivers

• Prevalence of Lennox-Gastaut Syndrome

According to National Organization for Rare Disease, around 1%-4 % of all cases of infantile epilepsy are caused by Lennox-Gastaut syndrome, which affects 0.1-0.28 people out of every 100,000 people. In addition to this, out of 100,000 children, 2 are thought to be affected by lennox-gastaut syndrome every year, whichcommonly appears between ages  2 to 7, with a peak onset between ages  3 and 5.

• Increasing Awareness About Lennox Gastaut Syndrome

The rising awareness about the diseased condition is spreading much awareness about the diagnosis and treatment of the same. Numerous governmental and non-governmental organizations such as Genetic and Rare Diseases (GARD) Information Center, Epilepsy Society, Genetic Alliance Australia, National Organization of Rare Disorders (NORD) are educating people and providing medical care and support to LGS patients. These organizations are raising awareness about the symptoms, diagnosis, signs, and treatment of LGS

Opportunities

• Rising Demand Of  Non-Surgical Treatment

The non-surgical treatment segment resulted in the highest Lennox-Gastaut syndrome treatment market share due to the recent LGS drug approvals and the higher adoption of ketogenic diet. Thus, this is creating much awareness about the market growth.

• Emergence of New Varied Treatments

Several companies are primarily focusing on the development of minimally invasive procedures such as MR-guided laser interstitial thermal therapy (MRg-LITT). MRg-LITT has become a safe, effective, and durable alternative to traditional open corpus callosotomy. The accurate efficacy of MRg-LITT is also being tested in advanced surgical ablation of epileptogenic foci and corpus callosotomy.

Restraints/Challenges

• Lack of Awareness

For many decades, epilepsy and seizures related disorders have been enveloped in discrimination, stigma, misinformation, and fear, in several parts of the world. The quality of life of people are used to be compromised due to disease's societal stigma, that still exists in many modern-day countries. The stigma connected with ailment may discourage some people from seeking treatment as they don't want to be identified with it.

• High Cost of Treatment Process

The huge expenditure required for its treatment processes impedes the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This  Lennox Gastaut syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Lennox Gastaut syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Lennox Gastaut Syndrome Market Scope

The Lennox Gastaut syndrome market is segmented on the basis of symptoms, route of administration, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Medication
• Surgery
• Intravenous Immunoglobulin Therapy
• Ketogenic Diet Products

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Lennox Gastaut Syndrome Market Regional Analysis/Insights

The Lennox Gastaut syndrome market is analyzed and market size insights and trends are provided by symptoms, route of administration, end-user distribution channel as referenced above.

The major countries covered in the Lennox Gastaut syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the high research and development activities in the neurology field and the strong presence of pharmaceutical industries.

Asia-Pacific is considered to grow over the coming years due to the rise in awareness, well-established healthcare infrastructure and rise in the healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Lennox Gastaut Syndrome Market Share Analysis

The Lennox Gastaut syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Lennox Gastaut syndrome market

Key players operating in the Lennox Gastaut syndrome market include:

• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• Bayer AG (Germany)
• Bristol Myers Squibb Company (U.S.)
• Novo Nordisk A/S (Denmark)
• GSK Plc. (U.K.)
• AstraZeneca (U.K.)
• Cadila Pharmaceuticals (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Amgen Inc. (U.S.)
• Abbott (U.S.)
• Sunovion Pharmaceuticals Inc (U.S.)
• Eisai Co., Ltd (Japan)
• Johnson & Johnson Private Limited (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Bausch Health Companies Inc. (Canada)
• H. Lundbeck A/S (Denmark)
• Marinus Pharmaceuticals, Inc (U.S.)

SKU-63160